Personalis, Inc. PSNL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +98.74%
- 1 year
- +66.35%
- Open
- 15.84
- Prev close
- 15.93
- Mkt cap
- 1.69B
- Vol
- 2.36M
- Avg vol
- 2.74M
- EPS
- -1.09
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.65
- High
- 15.91
- Forward P/E
- -16.37
- Beta
- 2.32
- Short ratio
- 2.95
- Inst. own
- 65.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 16.36
- 200-d avg
- 11.25
- 1y target
- 15.17
5D chart
Signals (55)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
News
2 days ago globenewswire.com
PSNL Investigation Reminder: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Hold Shares
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
3 days ago newsfilecorp.com
PSNL Merger Notice: BFA Law Notifies Personalis Shareholders of the Ongoing Investigation into the $16.25 per Share Merger
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders…
4 days ago globenewswire.com
$PSNL Stock Market Alert: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Are a Shareholder
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
5 days ago 247wallst.com
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the…
5 days ago prnewswire.com
PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders…
6 days ago globenewswire.com
PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.'s Directors and Officers for Breach of Fiduciary Duties – PSNL
Scott+Scott Attorneys at Law LLP is investigating whether the directors of Personalis, Inc. breached their fiduciary duties to Personalis's shareholders.
6 days ago globenewswire.com
$PSNL Merger Investigation: BFA Law Reminds Personalis Shareholders of Its Ongoing Investigation into the $16.25 per Share Merger Deal
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
1 week ago newsfilecorp.com
Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders…
1 week ago globenewswire.com
PSNL Investigation News: Personalis, Inc. Investors are Notified of the Pending Investigation into Ongoing Merger – Contact BFA Law if You Hold Shares
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
1 week ago prnewswire.com
Are VRNS, DSGR, PSNL Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
1 week ago newsfilecorp.com
PSNL Securities Notice: Personalis, Inc. Shareholders Are Notified to Contact BFA Law About Its Pending Investigation into the $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders…
1 week ago gurufocus.com
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced -- Investors are Alerted to Contact BFA Law
Leading securities law firm [url="]Bleichmar Fonti and Auld LLP[/url] announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ
1 week ago businesswire.com
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $PSNL #Acquisition--Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law.
1 week ago businesswire.com
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations…
1 week ago businesswire.com
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental…
3 weeks ago benzinga.com
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
3 weeks ago benzinga.com
This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.
1 month ago defenseworld.net
Aaron Tachibana Sells 2,931 Shares of Personalis (NASDAQ:PSNL) Stock
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CFO Aaron Tachibana sold 2,931 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22,…
1 month ago defenseworld.net
Stephen Michael Moore Sells 2,068 Shares of Personalis (NASDAQ:PSNL) Stock
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) SVP Stephen Moore sold 2,068 shares of the business's stock in a transaction dated Friday, September 18th. The stock was sold at an average price of…
1 month ago defenseworld.net
Richard Chen Sells 3,998 Shares of Personalis (NASDAQ:PSNL) Stock
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CMO Richard Chen sold 3,998 shares of the company's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an…
1 month ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
1 month ago defenseworld.net
Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 7,459 Shares
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CEO Christopher Hall sold 7,459 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
-
2 months ago benzinga.com
On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M
On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order…
2 months ago benzinga.com
Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
-
2 months ago benzinga.com
Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 15.38 percent. This is a 30.43 percent decrease over losses of…
3 months ago benzinga.com
Benzinga Bulls and Bears: IBM, Super Micro, Tesla
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
3 months ago benzinga.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
3 months ago benzinga.com
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holding while analysts see nearly 38% upside. Here's what the chart says.
-
3 months ago benzinga.com
Lake Street Downgrades Personalis to Hold, Announces $16.25 Price Target
Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announces $16.25 price target.
-
3 months ago benzinga.com
BTIG Maintains Buy on Personalis, Raises Price Target to $16.25
BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $11 to $16.25.
3 months ago benzinga.com
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
-
3 months ago benzinga.com
Tempus AI To Acquire Personalis In $1.5B Deal, Expanding Minimal Residual Disease Capabilities And Precision Medicine Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growthExpands…
-
3 months ago benzinga.com
Needham Maintains Buy on Personalis, Raises Price Target to $17
Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $12 to $17.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
-
3 months ago benzinga.com
Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test
This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and…
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $13
Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and raises the price target from $9 to $13.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
11 months ago benzinga.com
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago benzinga.com
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
1 year ago benzinga.com
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session